<DOC>
	<DOCNO>NCT02958202</DOCNO>
	<brief_summary>The aim study provide continue access BMN 044 treatment subject previously treat BMN 044 . The information gain study expect characterize efficacy safety BMN 044 longer treatment period .</brief_summary>
	<brief_title>Extension Study BMN 044 Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>This phase 2 multi center , multi national , open label , long term extension study . Up approximately 50 male subject Duchenne Muscular Dystrophy ( DMD ) previously treat BMN 044 enrol . Subjects receive either IV infusion SC injection pre-defined dos . Safety tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) efficacy assessment conduct regular interval throughout study . Subjects permit continue study subject meet define withdrawal criterion , BioMarin decide halt clinical development BMN 044 , BMN 044 receives market authorization .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Subjects previously treat BMN 044 comparator treatment BMN 044 Sponsored Study Investigator Initiated Trial eligible another ongoing BMN 044 study . Continued use glucocorticosteroids minimum 60 day prior study entry reasonable expectation subject remain glucocorticosteroids duration study . Willing able comply study requirement procedure . Willing able provide write , sign informed consent , case subject age 18 year ( 16 year , depend region ) , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior conduct researchrelated procedure . Subjects previously treat BMN 044 serious adverse experience meet safety stop criterion , remain unresolved , opinion Investigator could attributable BMN 044 . History significant medical disorder may confound interpretation safety data Acute illness within 4 week prior first dose BMN 044 ( Week 1 ) may interfere measurement . Symptomatic cardiomyopathy . Baseline aPTT upper limit normal ( ULN ) . Baseline platelet count lower limit normal ( LLN ) . Use anti coagulant , anti thrombotics anti platelet agent within 28 day baseline visit . Prior use investigational product ( BMN 044 ) investigational medical device must discuss Medical Monitor prior screen . Current history drug and/or alcohol abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>Dystrophin</keyword>
	<keyword>BMN 044</keyword>
	<keyword>PRO044</keyword>
	<keyword>BioMarin</keyword>
</DOC>